Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 4/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | TNIK | Q9UKE5 | 5/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22988855 | 0.82 | CSF1R (0.47) | MAP3K11NTRK1TNIKCYP3A4CYP2C19 | |
| SCHEMBL29414456 | 0.73 | GRM5 (0.56) | MTORCYP2C19 | |
| SCHEMBL107791 | 0.73 | GRM5 (0.56) | MTORCYP2C19 | |
| SCHEMBL24758083 | 0.73 | MAP3K11 (0.47) | MAP3K11TNIK | |
| SCHEMBL29883593 | 0.72 | CYP3A4 (0.63) | MAP3K11GPR84CYP3A4CYP2C19 | |
| SCHEMBL15102137 | 0.72 | CYP3A4 (0.63) | MAP3K11GPR84CYP3A4CYP2C19 | |
| SCHEMBL22989186 | 0.71 | CYP3A4 (0.43) | MAP3K11CYP3A4CYP2C19 | |
| SCHEMBL22978460 | 0.71 | CSF1R (0.60) | MAP3K11CYP3A4CYP2C19 | |
| SCHEMBL22989196 | 0.71 | MAPK1 (0.49) | MTORCYP3A4CYP2C19 | |
| SCHEMBL22989191 | 0.71 | CSF1R (0.49) | CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018233526-A9 | CSF1R INHIBITOR, AND MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | JAK2, JAK3, PAK3 | MAP3K11 128/4885NTRK1 1259/4885GPR84 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.